Taken together, we propose that a dual targeting approach combining a DYRK1B antagonist with an inhibitor of the PI3K/mTOR/AKT pathway has a pronounced impact on the GLI1 oncoprotein and exerts strong cytotoxic effects in cancer cells. The gene discussed is DYRK1B; the disease is cancer.